Drug Landscape ›
GOSERELIN ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 3,458
Most-reported reactions
Malignant Neoplasm Progression — 608 reports (17.58%) Neutropenia — 436 reports (12.61%) Fatigue — 425 reports (12.29%) Metastases To Bone — 350 reports (10.12%) Death — 311 reports (8.99%) Diarrhoea — 277 reports (8.01%) Nausea — 274 reports (7.92%) Metastases To Liver — 270 reports (7.81%) Asthenia — 261 reports (7.55%) Off Label Use — 246 reports (7.11%)
Source database →
GOSERELIN in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is GOSERELIN approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for GOSERELIN in United States?
Marketing authorisation holder not available in our data.